• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Centers for Medicare and Medicaid Services (CMS)

Report: Drugmakers may have ducked $1.3B in Medicaid rebates

December 21, 2017 By Sarah Faulkner

CMS

Without calling out any drug companies by name, the U.S. Dept. of Health and Human Services’ Office of Inspector General revealed this week that 10 potentially misclassified drugs may have resulted in $1.3 billion in lost rebates to Medicaid between 2012 and 2016. The issue of ducking rebates came to the public’s attention earlier this […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS)

Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification

August 17, 2017 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) said today that it inked a $465 million deal with U.S. Dept. of Justice to settle claims that it misclassified its EpiPen allergy auto-injector device with the Medicaid Drug Rebate Program. In October last year, The Centers for Medicare & Medicaid Services said that Mylan had been overcharging Medicaid for its EpiPen device for years, […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Mylan, Sanofi-Aventis

Kentucky doc gets jail time for bad opioid prescription habits & Medicaid fraud

June 7, 2017 By Sarah Faulkner

Prescription drugs

Dr. George Kudmani, an OB/GYN from Kentucky, was sentenced to 4 years in prison this week after a federal jury ruled that he was guilty of inappropriately doling out opioids and Medcaid fraud. The jury found Kudmani guilty of 19 counts of unlawful distribution of controlled substances and 8 counts of health care fraud. After Kudmani serves his […]

Filed Under: Featured, Hospital Care, Legal News, Pharmaceuticals, Women's Health Tagged With: Centers for Medicare and Medicaid Services (CMS)

Trump proposes deep cuts to Medicaid, NIH funding

May 23, 2017 By Sarah Faulkner

Capitol Hill

President Donald Trump’s proposed budget would slash Medicaid funding and cut support for major biomedical research programs at the National Institutes of Health and the Centers for Disease Control & Prevention. The budget blueprint drew condemnation from healthcare advocates and lawmakers from both sides of the aisle. Senate majority whip Sen. John Cornyn (R-Texas) reportedly said earlier […]

Filed Under: Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Centers for Medicare and Medicaid Services (CMS), National Institutes of Health

EpiPen purchasers level class action against Mylan over price hikes

April 4, 2017 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) was hit with another class action lawsuit over the price of its EpiPen device yesterday. The lawsuit, which was filed in the Washington Western District Court, alleges that Mylan engaged in a scheme with pharmacy benefit managers to dominate the market and overcharge customers. Although the Canonsburg, Penn.-based company has been hit with several lawsuits […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), CVS Health, Express Scripts, Mylan, OptumRx, U.S. Justice Dept.

CMS updates on criteria for Dexcom G5 coverage

March 24, 2017 By Sarah Faulkner

Dexcom

Shares in DexCom Inc. (NSDQ:DXCM) jumped 9% today after the Centers for Medicare & Medicaid Services updated the criteria for coverage of the company’s G5 Mobile continuous glucose monitor. The device is the only therapeutic CGM classified as durable medical equipment under Medicare Part B. Patients covered by Medicare who have Type I or II diabetes and […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), DexCom Inc.

Mylan recalls 81,000 EpiPens over reports of device failure

March 23, 2017 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) recalled 81,000 EpiPen emergency allergy auto-injectors this week after receiving 2 reports that the device failed to work in emergencies. The recall affects devices in Australia, New Zealand, Europe and Japan, the company reported. Canonsburg, Penn.-based Mylan said that in both cases, patients received treatment using an alternate EpiPen. The drugmaker also said that it […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Mylan

Senate confirms Verma to head CMS as debate intensifies over Obamacare replacement

March 14, 2017 By Sarah Faulkner

capitol hill

The U.S. Senate voted yesterday 55-43 to confirm Seema Verma to head the Centers for Medicare and Medicaid Services. Verma is the founder & CEO of SVC Inc, a healthcare consulting firm, and worked with now-Vice President Mike Pence when he was governor of Indiana to redesign the state’s Medicaid program. Get the full story […]

Filed Under: Featured, Policy, Wall Street Beat Tagged With: Capitol Hill, Centers for Medicare and Medicaid Services (CMS)

CMS nominee Verma: Mylan’s EpiPen case ‘disturbing’

February 17, 2017 By Sarah Faulkner

Mylan

Seema Verma, the nominee to head the Centers for Medicare & Medicaid, said at her confirmation hearing that she would like to review the way pharmaceutical companies classify products as generic or branded, citing the case of Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device. Mylan faced criticism this year for classifying EpiPen as a generic and paying smaller rebates to Medicaid […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Policy, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Mylan

Dexcom surges on Medicare nod for continuous glucose monitors

January 13, 2017 By Sarah Faulkner

Dexcom

DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s Dexcom G5 Mobile is the only CGM system that falls under this classification, according to San Diego, Calif.-based DexCom, since patients can make treatment decisions using the device. DXCM […]

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Abbott Laboratories, Centers for Medicare and Medicaid Services (CMS), DexCom Inc., Senseonics, Tandem Diabetes Care

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS